Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.

Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression. - Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050723

Enrollment

200

Registered

2023-03-30

Start date

2023-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients who received nivolumab and ipilimumab (+chemotherapy) or chemotherapy with single agent immune checkpoint inhibitor in 1st line setting for advanced recurrent non-small cell lung cancer. Definition of "advanced recurrence": Patients with 1 Stage III not radically irradiated 2 Stage IV 3 Postoperative recurrence 4 Recurrence after radiotherapy alone 2 Patients for whom information on medical treatment and prognosis can be obtained from medical records 3 Patients over 20 years old 4 Patients with low(1-49%)/negative PD-L1 expression.

Exclusion criteria

Exclusion criteria: (i) Patients who have requested not to participate in this study based on publicly available information. (ii) Other patients deemed ineligible by the principal investigator

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
Progression-Free Survival Rate (12 and 24 months) Overall survival (OS) Survival rate (12 and 24 months) Objective Response Rate (ORR)	—

Countries

Japan

Contacts

Public ContactFukui Takafumi

Kobe University Graduate School of Medicine Division of Respiratory Medicine/Department of Internal Medicine

konkon@med.kobe-u.ac.jp078-382-5660

Outcome results